CytoSorb® is CE-mark approved in the E.U. In the U.S., CytoSorb® and DrugSorb-ATR® are investigational devices not yet FDA authorized/approved/cleared.
Content dedicated only to Investor Relationsback to cytosorbents.com

Investor Relations

CytoSorbents

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at https://ir.cytosorbents.com/